Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Airway Therapeutics, Inc. secures $50 million in Series E-2 funding to advance the clinical development of Zelpultide alfa. The funding round saw participation from existing investors, including Cincinnati Children's Hospital.
PRIVATEAug 25, 2026•about 4 hours ago
Amount Raised
$50 Million
Round Type
Series E
AtlantaBiotechnologyHealth CareTherapeutics
Investors
Cincinnati Children's Hospital
Description
Airway Therapeutics, Inc. announced a successful financing round of $50 million to support the late clinical development of Zelpultide alfa. The Series E-2 funding consists of $24 million raised and $26 million previously secured through a SAFE financing. The funds will primarily aid in completing Phase 2b/3 clinical studies and related activities
Company Information
Company
Airway Therapeutics
Location
Atlanta, Georgia, United States
About
Airway Therapeutics is a biopharmaceutical company developing a new class of biologics aimed at breaking the cycle of injury and inflammation for patients with respiratory and inflammatory diseases. The company is advancing zelpultide alfa, a novel recombinant human protein hSP-D that reduces inflammation and infection while modulating the immune response. Zelpultide alfa is targeted for preventing bronchopulmonary dysplasia in very preterm infants. The firm is committed to addressing the needs of the most vulnerable populations.
Don't miss Airway Therapeutics's next move
Get an email the moment Airway Therapeutics raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Airway Therapeutics's next move
AtlantaBiotechnologyHealth CareTherapeutics